Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity.

Mikhael, Nadia Z.; Nanji, Amin A.; Nair, Rama C.; Kacew, Sam; Howard, Katherine M.; Hirte, Wolfgang; Maroun, J.

doi:10.1200/jco.1985.3.9.1251

Cited by 62 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies performed within 15 months after cisplatin administration, [48][49][50][51] show increased platinum levels in most organs. In human autopsies conducted 4 to 867 days after the last cisplatin dose, platinum concentrations were highest in dorsal root ganglia and lowest in tissues protected by the blood-brain barrier, in line with observations of sensory neuropathies and histopathologically documented peripheral nerve damage.…”

Section: Discussionmentioning

confidence: 99%

Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer

Sprauten

Darrah

Peterson

et al. 2012

JCO

161

View full text Add to dashboard Cite

A B S T R A C T PurposeCisplatin-induced neurotoxicity and ototoxicity (NTX) are important adverse effects after chemotherapy for testicular cancer (TC). Although serum platinum is measurable years after therapy, its impact on NTX has not been evaluated. Patients and MethodsIn all, 169 cisplatin-treated survivors of TC provided blood samples at Survey I and reported NTX during Survey I (1998Survey I ( -2002 and Survey II (2007. Serum platinum was quantified by inductively coupled plasma mass spectrometry. Patient-reported outcomes were evaluated with the Scale for Chemotherapy-Induced Neurotoxicity (SCIN), regarding the extent of symptom bother as 0, "not at all"; 1, "a little"; 2, "quite a bit"; or 3, "very much." Summing the six symptom scores yielded a total SCIN score of 0 to 18. Categorizing total SCIN scores into quartiles yielded similar-sized groups with increasing symptoms. Multivariate ordinal logistic regression analyses evaluated associations between NTX and long-term serum platinum levels, adjusting for cisplatin dose, dosing schedule, and age. ResultsAt Survey I, a significant four-to five-fold association with total SCIN score emerged for the highest serum platinum quartile (odds ratio [OR], 4.69; 95% CI, 1.82 to 12.08). Paresthesias and Raynaud's syndrome (hands and feet) showed significant two-to four-fold increased risks with the highest platinum quartile. At Survey II, total SCIN score remained significantly associated with the highest platinum quartile (OR, 4.28; 95% CI, 1.36 to 13.48). Paresthesias (hands and feet) and tinnitus showed significant three-to four-fold increased risks for the highest platinum quartile. Cumulative cisplatin dose was not associated with total SCIN score or individual SCIN symptoms in multivariate analyses. ConclusionHere we document a significant relationship between increasing levels of residual serum platinum and NTX severity after adjusting for initial cisplatin dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer

Sprauten

Darrah

Peterson

et al. 2012

JCO

161

View full text Add to dashboard Cite

show abstract

“…The question of cumulative toxicity is more controversial. Some have reported cumulative and unpredictable nephrotoxicity (Goren et al, 1986) while others have related cumulative toxicity to renal cortical platinum concentrations (Stewart et al, 1985). Others have denied any cumulative toxicity (Meijer et al, 1982;Chiuten et al, 1983) (Daugaard et al, 1988), in the stable pretreatment or long post-treatment situation an excellent correlation between serum creatinine and GFR is seen (Daugaard et al, 1988) and indeed some have suggested that serum creatinine is the preferred measure of GFR (Payne, 1986).…”

Section: Renal Functionmentioning

confidence: 99%

Long-term toxicity of chemotherapy for testicular cancer – the cost of cure

Stuart

Woodroffe²,

Grundy³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Twenty-seven patients cured of advanced testicular cancer by cisplatin-based chemotherapy have been assessed, a median of 30 months after start of treatment, for the long-term effects of such treatment on renal, endocrine, audiometric, reproductive and respiratory function. To control for the effects of orchidectomy on endocrine function a similar group of 11 patients cured by orchidectomy alone was also assessed. The extents of impairment in hearing and renal function were related to the total dose of cisplatin received, while the majority of patients had respiratory impairment which was, in part, related to the total dose of bleomycin. TSH was significantly higher in the chemotherapy group although serum free thyroxine and free T3 were normal in all. FSH was raised in 67% of the chemotherapy group and in 45% of the orchidectomy group while LH was raised in 75% and 45% respectively. Serum testosterone was normal in all. MethodsClinical notes were reviewed to obtain details of investigations at presentation and of chemotherapy received. Hepatic and renal function, serum TSH, free thyroxine and free T3, serum FSH, LH and testosterone, tumour markers (afetoprotein and P-human chorionic gonadotrophin) and full blood count were measured. Standard laboratory normal ranges were used and serum hormones were measured by specific immunometric methods.Pulmonary function assessment comprised measurement of vital capacity (VC), forced residual capacity (FRC), residual volume (RV), total lung capacity (TLC), forced expiratory capacity in one second (FEV,), peak expiratory flow rate (PFR), transfer factor coefficient (KCO), total lung transfer factor (TLCO), total alveolar volume (TAV) and effective alveolar volume (EAV). TLCO was measured by single breath-hold method with correction for haemoglobin concentration, EAV by single breath helium dilution and lung volumes by steady state helium dilution. Values other than TAV and EAV were expressed as standardised residuals (Miller & Pincock, 1988) with expected values determined from height and age by published regression equations (European Coal and Steel Community Recommendations, 1983

show abstract

“…11 There is evidence that renal cortical platinum accumulation is significantly associated with increase in serum creatinine. 12 The mean serum creatinine values were stable and well within the normal range throughout the audit period (Table 1). This may be explained by patients receiving adequate hydration.…”

Section: Discussionmentioning

confidence: 98%

Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas

Zekri

Nl²,

Evans³

et al. 2009

JRCPE

View full text Add to dashboard Cite

Etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) is one of the mostly widely used chemotherapy regimens for patients with relapsed lymphomas. Cisplatin administration is commonly associated with electrolyte imbalance. Careful monitoring of renal function and serum electrolytes is therefore essential in this setting. Aims: To review the practice of electrolyte monitoring -potassium (K), calcium (Ca) and magnesium (Mg) -in patients receiving ESHAP and the frequency and severity of abnormalities and their management. Methods: Twenty-one consecutive patients received ESHAP. The medical records of 16 patients were retrievable and reviewed retrospectively. Results of serum K, Ca and Mg were collected prior to and after cycles 1, 2 and 3 of ESHAP, if measured. Results: Serum K levels prior to every cycle did not show any noticeable change. The means were 4.42, 4.34 and 4.43 mmol/l before cycles 1, 2 and 3, respectively. In one patient hypokalaemia was severe, refractory and symptomatic when preceded by hypomagnesaemia. Serum-adjusted calcium levels showed only minimal reduction. The means were 2.46, 2.40 and 2.38 mmol/l before cycles 1, 2 and 3 respectively. Mean serum Mg levels prior to every cycle showed progressive reduction; 0.84, 0.75 and 0.67 mmol/l before cycles 1, 2 and 3, respectively. This was associated with a progressive increase in the amount of required Mg supplementation. Serum K, Ca and Mg was measured prior to 100%, 67% and 35% of administered cycles, respectively. Conclusion: In patients receiving ESHAP, hypokalaemia can occasionally be seen, especially if preceded by hypomagnesaemia. Mild cumulative hypocalcaemia is recognised. Hypomagnesaemia is a progressive complication and physicians need be aware of its importance.

show abstract

Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity.

Cited by 62 publications

References 16 publications

Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer

Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer

Long-term toxicity of chemotherapy for testicular cancer – the cost of cure

Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas

Contact Info

Product

Resources

About